Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

HitGen to Discover Lead Molecules for Takeda

publication date: Sep 11, 2017

HitGen. the Chengdu-Houston lead-generation CRO, signed a deal to discover novel drug leads for Japan's Takeda Pharma. HitGen will search its DNA encoded chemical libraries, which HitGen says contain over 90 billion novel drug-like small molecule and macrocycle compounds, for likely candidates. The Takeda collaboration is the third that HitGen has announced in the last month. As usual, HitGen will receive an upfront payment plus milestones, though it doesn't release specifics. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital